Alexander M Frankell
Overview
Explore the profile of Alexander M Frankell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
484
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Middleton G, Robbins H, Fletcher P, Savage J, Mehmi M, Summers Y, et al.
NPJ Precis Oncol
. 2025 Mar;
9(1):67.
PMID: 40069402
There are no current stratified medicine options for STK11-deficient NSCLC. STK11 loss mediates mTORC activation, GLUT1 up-regulation and increased glycolysis. This metabolic reprogramming might represent a therapeutic vulnerability targetable with...
2.
Black J, Bartha G, Abbott C, Boyle S, Karasaki T, Li B, et al.
Nat Med
. 2025 Jan;
31(1):70-76.
PMID: 39806071
Circulating tumor DNA (ctDNA) detection can predict clinical risk in early-stage tumors. However, clinical applications are constrained by the sensitivity of clinically validated ctDNA detection approaches. NeXT Personal is a...
3.
Biswas D, Liu Y, Herrero J, Wu Y, Moore D, Karasaki T, et al.
Nat Cancer
. 2025 Jan;
6(1):86-101.
PMID: 39789179
Human tumors are diverse in their natural history and response to treatment, which in part results from genetic and transcriptomic heterogeneity. In clinical practice, single-site needle biopsies are used to...
4.
Characterizing the evolutionary dynamics of cancer proliferation in single-cell clones with SPRINTER
Lucas O, Ward S, Zaidi R, Bunkum A, Frankell A, Moore D, et al.
Nat Genet
. 2024 Nov;
57(1):103-114.
PMID: 39614124
Proliferation is a key hallmark of cancer, but whether it differs between evolutionarily distinct clones co-existing within a tumor is unknown. We introduce the Single-cell Proliferation Rate Inference in Non-homogeneous...
5.
Frankell A, Dietzen M, Al Bakir M, Lim E, Karasaki T, Ward S, et al.
Nature
. 2024 Jul;
631(8022):E15.
PMID: 38965439
No abstract available.
6.
Hobor S, Al Bakir M, Hiley C, Skrzypski M, Frankell A, Bakker B, et al.
Nat Commun
. 2024 Jun;
15(1):4871.
PMID: 38871738
The phenomenon of mixed/heterogenous treatment responses to cancer therapies within an individual patient presents a challenging clinical scenario. Furthermore, the molecular basis of mixed intra-patient tumor responses remains unclear. Here,...
7.
Grigoriadis K, Huebner A, Bunkum A, Colliver E, Frankell A, Hill M, et al.
Nat Protoc
. 2023 Nov;
19(1):159-183.
PMID: 38017136
Intratumor heterogeneity provides the fuel for the evolution and selection of subclonal tumor cell populations. However, accurate inference of tumor subclonal architecture and reconstruction of tumor evolutionary histories from bulk...
8.
Abbosh C, Frankell A, Harrison T, Kisistok J, Garnett A, Johnson L, et al.
Nature
. 2023 Apr;
616(7957):553-562.
PMID: 37055640
Circulating tumour DNA (ctDNA) can be used to detect and profile residual tumour cells persisting after curative intent therapy. The study of large patient cohorts incorporating longitudinal plasma sampling and...
9.
Frankell A, Dietzen M, Al Bakir M, Lim E, Karasaki T, Ward S, et al.
Nature
. 2023 Apr;
616(7957):525-533.
PMID: 37046096
Lung cancer is the leading cause of cancer-associated mortality worldwide. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell...
10.
Al Bakir M, Huebner A, Martinez-Ruiz C, Grigoriadis K, Watkins T, Pich O, et al.
Nature
. 2023 Apr;
616(7957):534-542.
PMID: 37046095
Metastatic disease is responsible for the majority of cancer-related deaths. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in...